Case Report

Recurrence of Cryptococcal Meningitis and the Hidden Role of Patient Education and Social Support

Felix Bongomin and Lorna Atikoro

1Department of Medical Microbiology & Immunology, Faculty of Medicine, Gulu University, P.O. Box 166, Gulu, Uganda
2Department of Medicine, Gulu Regional Referral Hospital, P.O. Box 180, Gulu, Uganda

Correspondence should be addressed to Felix Bongomin; felix.ayoli9@gmail.com

Received 28 May 2018; Accepted 1 August 2018; Published 8 August 2018

1. Introduction

Cryptococcal meningitis (CM) is a community-acquired opportunistic fungal infection of the central nervous system caused by Cryptococcus species of yeasts. CM is the second most common HIV-associated opportunistic infection worldwide and has become one of the leading causes of death among patients living with HIV/AIDS in resource-limited settings, causing for ~15-20% of AIDS-related deaths globally [1]. About 73% of the over 200,000 estimated global annual cases of CM occur in Sub-Saharan Africa [2, 3].

Unlike bacterial and viral meningitis, adjunctive corticosteroid therapy is contraindicated for the management of CM and treatment is always long-term consisting of three phases: 2 weeks of induction therapy with amphotericin B plus flucytosine, and a further 8-10 weeks of consolidation with fluconazole 400-800mg daily followed by long-term fluconazole (200mg daily) therapy for maintenance phase, also known as secondary prophylaxis for at least 1 year [4–6]. The most recent evidence from the Advancing Cryptococcal meningitis Treatment for Africa (ACTA) randomised clinical trial suggests that short-course induction therapy (amphotericin B for 7 days + fluconazole or flucytosine) is safer and more efficacious than the current standard of care (amphotericin B for 14 days plus fluconazole or flucytosine) [7]. Short-course induction therapy is now the World Health Organization (WHO) preferred regimen [8]. Without secondary prophylaxis, recurrence of cryptococcal meningitis occurs in nearly half of the patients [9]. Previous studies have shown that relapses of symptomatic CM are often associated with fluconazole resistance and immune reconstitution inflammatory syndrome [10]. However, a recent systematic review suggest that fluconazole resistance does not explain all cases of CM relapses [11].

We present our experience with a patient who had a recurrent cryptococcal disease due to nonadherence to HIV care and lack of awareness of the benefit of adherence to secondary prophylaxis for CM.
by Kernig’s technique; however, pupils were equal, accommodative, and reactive to light. Her blood pressure was 115/70 mmHg, pulse rate was 100 beats per minute, respiratory rate was 16 breaths per minute, and her body temperature was 37.5°C. Rapid diagnostic test for malaria was negative and random blood sugar was within normal limits. She was stabilized and managed conservatively. After a couple of hours at the emergency unit, she gained consciousness and was able to share her history of current illness. She reported progressive worsening of a headache, with no history of convulsions, fever, or visual disturbances. Review of other systems was noncontributory.

In her past medical history (PMH), she was diagnosed with HIV infection in November of 2016 following an admission at GRRTH for an acute illness. She had presented with CM as her index opportunistic infection. She reported a history of a severe headache and fever for about 3 weeks prior to her admission. Diagnosis of CM was achieved through examination of Cerebrospinal fluid (CSF) following a diagnostic lumbar puncture (LP). She was treated with fluconazole 1200mg daily for 2 weeks and then discharged home on 800mg daily by mouth. During this admission, she was also initiated on antiretroviral therapy (ART) consisting of Tenofovir/Lamivudine/Efavirenz. A follow-up date was given a month from the date of discharge. However, she did not return to the hospital on the given follow-up date, as she did not have the transport money to come to the hospital. Since then, she discontinued fluconazole therapy and was not also on ART.

From her presentation and PMH, a recurrence of CM was the most likely diagnosis. Diagnostic LP was done to obtain CSF for analysis; serum and CSF point-of-care lateral flow assays were both positive for cryptococcal antigen (CrAg: Immuno-Mycologics [IMMY], Oklahoma, USA). Microscopic examination of an India ink preparation of the CSF demonstrated numerous budding yeast cells [Figure 1] consistent with morphologic identification of Cryptococcus species, confirming the clinical diagnosis. CSF fungal culture was not done.

Since amphotericin B was “out-of-stock” and fluconazole is not available in Uganda, for induction phase, she was treated with high dose (1200mg) fluconazole and she also received daily therapeutic LPs over 72 hours for the management of her assumed increased intracranial pressure (deferred from her very severe headaches). She reported some improvement after 2 weeks of treatment. Fluconazole dose was reduced to 800mg daily as per the national CM treatment guidelines. A repeat HIV antibody test was positive, she had a CD4 count of 79 cells/µL, and her blood samples were sent for viral load assay at the Uganda Virus Research Institute, Entebbe. She was recommenced on ART in the 5th week of her CM treatment.

She was not aware of the cause, treatment options, and duration and the need for long-term/life-long suppression therapy for her condition. She comes from Pakwach, West Nile (~120KM from Gulu) [Figure 2], and was working as a bar waitress to earn a living in Gulu. She had no caretaker and did not have money to take care of her basic needs while in the hospital. She mostly relied on the support of good Samaritans and the support of other patient’s caretakers for food and support. Through connections with another patient’s caretaker, her brother was contacted and he requested that she is discharged and transferred for further care at Arua Regional Referral Hospital (~107KM from Pakwach) [Figure 2], as they did not have the financial resources to sustain her in Gulu. We lost contact with her thereafter.

3. Discussion

Long-term (at least 12 months) or life-long secondary prophylaxis with fluconazole or an alternative antifungal agent is always required, and it is associated with reduction in the
rate of recurrence of CM from about 50% to under 5% [9]. The present case study adds to the evidence that reasons for recurrent disease is multifactorial and goes beyond clinical, microbiological, or pharmacological (treatment) realm. A well-tailored patient counseling and education and social support including home visits improves awareness, increases adherence, and reduces disengagement rate from chronic HIV/CM care. Adapted adherence support has recently been included in the WHO advanced HIV disease package of care [12].

Our patient had several reasons to explain the recurrence of her CM including, suboptimal therapy, poor adherence and compliance, lack of social support, and economic challenges. Importantly, disengagement from both CM and HIV care due to the above challenges contributed to disease progression in this case. Bicanic and colleagues reported that symptomatic relapse of HIV-associated CM is common after initial fluconazole monotherapy with an associated 6-month mortality in excess of 50% [10].

Emerging evidence from an ongoing trial suggests that weight based initial fluconazole dose of 1600mg is more effective than the current WHO recommended dose (1200mg) and safer than 2000mg but less effective than amphotericin B across all doses [13]. It is clear that amphotericin B based induction is the treatment of choice as per current treatment guidelines based on the best available evidence. Moreover, the ACTA trial showed that 2-week induction therapy with all-oral regimen (fluconazole and flucytosine) is as effective as short-course amphotericin B based regimen. Advocacy should be put across to make flucytosine available in areas of dire need as it has been shown to have super early fungicidal activity especially as a partner drug to amphotericin B [7].

Despite ART expansion, in many parts of the world, the morbidity and mortality attributable to cryptococcal disease are largely unchanged in low-income and middle-income countries [14, 15]. Cryptococcus is the most common cause of meningitis in Uganda both in patients newly diagnosed with HIV and in known HIV-infected patients who are not on ART [16]. Improved management (treatment and prophylaxis) of CM among HIV/AIDS patients receiving ART is essential to reducing ongoing AIDS mortality [16]. Effective induction therapy requires potent fungicidal drugs (amphotericin B and flucytosine) [7, 17], which are often unavailable in low-resource, high-endemicity settings. As a consequence, mortality is unacceptably high [18]. All antifungal agents for the treatment of CM are on the WHO Essential Medicine List. Fluconazole is available in almost all countries across the world. However, amphotericin B and flucytosine remain unavailable in many parts of Sub-Saharan Africa [19].

The most common causes of recurrent symptoms and signs of CM are nonadherence to consolidation fluconazole therapy or secondary prophylaxis, nonadherence to ART, mycological relapse (with a positive CSF culture of Cryptococcus), and paradoxical cryptococcal-immune reconstitution inflammatory syndrome [10, 20]. Compliance is dependent on an unlimited supply of antifungal agents for the entire period of secondary prophylaxis (12 months or more); these require a strong socioeconomic support to the patients and the ability of the patients to reach the health facilities. Public health and clinical attention are mostly on optimization of antifungal therapy and screening for asymptomatic ant igenemia [21]; very limited or no attention has been given to the social and economic challenges faced by these patients.

This case is of particular interest as it does not only support the growing evidence that a considerable proportion of patients represent to care with advanced HIV disease and life-threatening opportunistic infection [22], but also that multiple factors are associated with poor clinical outcomes. The roles of social support and patient education in recovery are the most neglected of these factors. We urge that fungal diseases awareness should not be limited only to the health professionals and public health practitioners, but also to patients and stakeholders. Educating the patient on the most relevant information including prognosis of CM and the need for long-term secondary prophylaxis, establishment of patient social support groups and possibility home delivery of antifungals in consolidation and suppression phases of CM management should be part and parcel of a comprehensive CM/HIV care. These should be incorporated into routine clinical care and included in the local practice guidance, especially in areas with high disease burden.

**Disclosure**

The authors confirm that all patient/personal identifiers have been removed or disguised so the patient/person(s) described are not identifiable and cannot be identified through the details of the story.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Acknowledgments**

The Global Action Fund for Fungal Infections (GAFFI) sponsored the filming of this patient for educational purposes.

**References**

[1] D. J. Sloan and V. Parris, “Cryptococcal meningitis: epidemiology and therapeutic options,” *Journal of Clinical Epidemiology*, vol. 6, no. 1, pp. 169–182, 2014.

[2] R. Rajasingham, R. M. Smith, B. J. Park et al., “Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis,” *The Lancet Infectious Diseases*, vol. 17, no. 8, pp. 873–881, 2017.

[3] J. N. Jarvis and T. S. Harrison, “HIV-associated cryptococcal meningitis,” *AIDS*, vol. 21, no. 16, pp. 2119–2129, 2007.

[4] J. R. Perfect, W. E. Dismukes, F. Dromer et al., “Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America,” *Clinical Infectious Diseases*, vol. 50, no. 3, pp. 291–322, 2010.

[5] J. N. Day, T. T. H. Chau, M. Wolbers et al., “Combination antifungal therapy for cryptococcal meningitis,” *The New England Journal of Medicine*, vol. 368, no. 14, pp. 1291–1302, 2013.
[6] J. Beardsley, M. Wolbers, F. M. Kibengo et al., "Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis," *The New England Journal of Medicine*, vol. 374, no. 6, pp. 542–554, 2016.

[7] S. F. Molloy, C. Kanyama, R. S. Heyderman et al., "Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa," *The New England Journal of Medicine*, vol. 378, no. 11, pp. 1004–1017, 2018.

[8] World Health Organization (WHO). Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. http://apps.who.int/iris/bitstream/handle/10665/260399/9789241550277-eng.pdf;jsessionid=703904B41E77B626A9D91FC7D27CC936?sequence=1.

[9] S. A. Bozzette, R. A. Larsen, J. Chiu et al., "A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group," *The New England Journal of Medicine*, vol. 324, no. 9, pp. 580–584, 1991.

[10] T. Bicanic, T. Harrison, A. Niepieklo, N. Dyakopu, and G. Meintjes, "Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution," *Clinical Infectious Diseases*, vol. 43, no. 8, pp. 1069–1073, 2006.

[11] F. Bongomin, R. O. Oladele, S. Gago, C. B. Moore, and M. D. Richardson, "A systematic review of fluconazole resistance in clinical isolates of," *Mycoses*, vol. 61, no. 5, pp. 290–297, 2018.

[12] World Health Organization (WHO). Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. http://apps.who.int/iris/bitstream/handle/10665/255885/WHO-HIV-2017.18-eng.pdf?sequence=1.

[13] U. G. Lalloo, A. Judith, H. Evelyn et al., "Higher high dose fluconazole for the treatment of cryptococcal meningitis," in *Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI)*, Boston, Massachusetts, 2018.

[14] B. J. Park, K. A. Wannemuehler, B. J. Marston, N. Govender, P. G. Pappas, and T. M. Chiller, "Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS," *AIDS*, vol. 23, no. 4, pp. 525–530, 2009.

[15] R. Rajasingham and D. R. Boulware, "HIV care: ART adherence support and cryptococcal screening," *The Lancet*, vol. 385, no. 9983, pp. 2128–2129, 2015.

[16] A. G. Flynn, D. B. Meyers, K. H. Hullsiek et al., "Evolving Failures in the Delivery of Human Immunodeficiency Virus Care: Lessons From a Ugandan Meningitis Cohort 2006–2016," *Open Forum Infectious Diseases*, vol. 4, no. 2, 2017.

[17] C. M. van der Horst, M. S. Saag, G. A. Cloud et al., "Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group," *The New England Journal of Medicine*, vol. 337, no. 1, pp. 15–21, 1997.

[18] D. J. Sloan, M. J. Dedicoat, and D. G. Lalloo, "Treatment of cryptococcal meningitis in resource limited settings," *African Health Sciences*, vol. 12, no. 2, pp. 226–230, 2012.

[19] Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. World Health Organization HIV/AIDS program. http://apps.who.int/iris/handle/10665/44786.

[20] N. Ford and M. Doherty, "The Enduring Challenge of Advanced HIV Infection," *The New England Journal of Medicine*, vol. 377, no. 3, pp. 283–284, 2017.